ロード中...
CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy
Glioblastoma is the most common and aggressive type of brain tumor with high recurrence and fatality rates. Although various therapeutic strategies have been explored, there is currently no effective treatment for glioblastoma. Recently, the number of immunotherapeutic strategies has been tested for...
保存先:
| 出版年: | Cancer Immunol Immunother |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Berlin Heidelberg
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8053161/ https://ncbi.nlm.nih.gov/pubmed/33128583 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-020-02742-1 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|